公开(公告)号：US12226469B2

公开(公告)日：2025-02-18

申请号：US17088683

申请日：2020-11-04

Applicant: Evaxion Biotech ApS

Inventor： Niels Iversen Møller ,  Andreas Holm Mattsson

IPC: A61K39/108 ,  A61K38/03 ,  A61K38/16 ,  C07K14/26 ,  C07K16/12 ,  C12N15/70 ,  C12N15/75 ,  C12N15/79 ,  G01N33/569

Abstract: The present invention relates to proteins and nucleic acids derived from Klebsiella pneumoniae as well as therapeutic and diagnostic uses of the proteins and nucleic acids.

公开(公告)号：US12220452B2

公开(公告)日：2025-02-11

申请号：US17684121

申请日：2022-03-01

Applicant: NantBio, Inc.

Inventor： Kayvan Niazi ,  Raymond Wong ,  Peter Sieling ,  Philip T. Liu

IPC: A61K39/02 ,  A61K39/00 ,  A61K39/108 ,  C12N15/861 ,  A61K9/00

Abstract: Two-component vaccine formulations and methods are contemplated where the vaccine has an adjuvant component and a therapeutic component. The therapeutic component comprises preferably a recombinant therapeutic virus encoding a therapeutic antigen while the adjuvant component comprises a non-host cell or immune stimulating portion thereof. Notably, use of the adjuvant component will result in significant uptake of the therapeutic component into immune competent cells, even in the absence of receptors for entry of the therapeutic component. In addition, such adjuvant also stimulates expression of the therapeutic antigen.

公开(公告)号：US12214029B2

公开(公告)日：2025-02-04

申请号：US18305948

申请日：2023-04-24

Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.

Inventor： Michael T. Kowarik ,  Michael L. Wetter ,  Stefan J. Kemmler ,  Micha A. Häuptle ,  Veronica Gambillara ,  Manuela Mally

IPC: A61K39/108 ,  A61K39/00 ,  A61K39/02 ,  A61K47/64 ,  C07K14/21 ,  C07K14/245 ,  C08B37/00

Abstract: Provided herein is an E. coli O polysaccharide, O25B. Also provided herein are prokaryotic host cells containing enzymes (e.g., glycosyltransferases) used in O25B production. The host cells provided herein produce O25B bioconjugates, wherein said bioconjugates contain O25B linked to a carrier protein. Further provided herein are compositions, e.g., pharmaceutical compositions, including O25B and/or bioconjugates containing O25B. Such compositions can be used as vaccines against infection with ExPEC, and may further include one or more additional bioconjugates.

公开(公告)号：US12214028B2

公开(公告)日：2025-02-04

申请号：US17615554

申请日：2019-05-31

Applicant: UNIVERSIDAD DE CHILE

Inventor： Roberto Mauricio Vidal Alvarez ,  Felipe Antonio Del Canto Fuentes ,  David Arturo Montero Forero ,  Juan Carlos Salazar Garrido

IPC: A61K39/02 ,  A61K39/108 ,  A61K47/64 ,  A61K47/69 ,  A61P31/04 ,  C07K14/245 ,  A61K39/00

Abstract: Disclosed is an immunogenic formulation that induces protection against Shiga Toxin-Producing Escherichia coli (STEC), the formulation comprising: one or more chimeric proteins derived wholly or in part from OmpT and Hes proteins of STEC; and at least one physiologically or pharmaceutically acceptable excipient, carrier and/or diluent.

公开(公告)号：US20250011375A1

公开(公告)日：2025-01-09

申请号：US18705332

申请日：2022-10-28

Applicant: Vaxxinova US, Inc.

Inventor： Graham J.M. Cox ,  Daryll Emery ,  Darren E. Straub ,  Lisa Herron-Olson ,  Patricia Tam ,  Drew M. Catron

IPC: C07K14/245 ,  A61K39/00 ,  A61K39/108 ,  A61P31/04 ,  C07K16/12 ,  C12N15/70

Abstract: The present invention provides isolated proteins isolatable from an E. coli, such as avian pathogenic E. coli. Also provided by the present invention are compositions that include one or more of the proteins, and methods for making and methods for using the proteins.

公开(公告)号：US20240293473A1

公开(公告)日：2024-09-05

申请号：US18424075

申请日：2024-01-26

Applicant: Viktor Veniaminovich TETS ,  Georgy Viktorovich TETS

Inventor： Viktor Veniaminovich TETS ,  Georgy Viktorovich TETS

IPC: A61K35/74 ,  A61K31/65 ,  A61K31/7004 ,  A61K33/06 ,  A61K35/745 ,  A61K35/747 ,  A61K35/76 ,  A61K38/08 ,  A61K38/17 ,  A61K38/46 ,  A61K39/00 ,  A61K39/108 ,  A61P3/10 ,  C07K16/12 ,  C12N15/113 ,  C12Q1/6883

CPC classification number: A61K35/74 ,  A61K31/65 ,  A61K31/7004 ,  A61K33/06 ,  A61K35/745 ,  A61K35/747 ,  A61K35/76 ,  A61K38/08 ,  A61K38/1709 ,  A61K38/465 ,  A61K39/0258 ,  A61P3/10 ,  C07K16/1232 ,  C12N15/113 ,  C12Q1/6883 ,  A61K2039/505 ,  C12N2310/14 ,  C12Q2600/118 ,  C12Q2600/156

Abstract: Methods for preventing, treating or diagnosing Type 1 Diabetes (T1D) are described. Amyloid-producing bacteria within microbiota are inactivated. Amyloid-producing bacteria are inactivated in microbiota, gastrointestinal tract, bodily fluids or tissues. Type-1 Diabetes associated microbial product production or release by microbiota is prevented. Also described is inactivation of bacteria-derived T1DAMP present in microbiota, bodily fluids or tissues of a mammal. Release of bacteria-derived T1DAMP from biofilm or bacteria to gastrointestinal tract is inhibited. Entry of bacteria-derived T1DAMP to microbiota, gastrointestinal tract, bodily fluids or tissues of a mammal is inhibited.

公开(公告)号：US20240277824A1

公开(公告)日：2024-08-22

申请号：US18402174

申请日：2024-01-02

Applicant: GLAXOSMITHKLINE BIOLOGICALS SA

Inventor： Fabiana FERNANDEZ ,  Michael KOWARIK ,  Michael WACKER ,  Michael WETTER

IPC: A61K39/112 ,  A61K39/00 ,  A61K39/02 ,  A61K39/104 ,  A61K39/108 ,  A61K39/385 ,  C07K14/195

CPC classification number: A61K39/0283 ,  A61K39/0258 ,  A61K39/104 ,  A61K39/105 ,  A61K39/385 ,  C07K14/195 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/6087 ,  C07K2319/034 ,  Y02A50/30

Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.

公开(公告)号：US20240254170A1

公开(公告)日：2024-08-01

申请号：US18594957

申请日：2024-03-04

Applicant: AgroSpheres, Inc.

Inventor： Ameer Hamza SHAKEEL ,  Sepehr ZOMORODI ,  Joseph Thomas FRANK ,  Zachery George DAVIS ,  Payam POURTAHERI

IPC: C07K14/195 ,  A01N25/28 ,  A01N63/22 ,  A01N63/50 ,  C07K14/32 ,  C07K14/335 ,  C07K14/34 ,  C12N1/08 ,  C12N9/52 ,  C12N9/54 ,  C12N15/62 ,  A61K39/108 ,  B01F101/04

CPC classification number: C07K14/195 ,  A01N25/28 ,  A01N63/22 ,  A01N63/50 ,  C07K14/32 ,  C07K14/335 ,  C07K14/34 ,  C12N1/08 ,  C12N9/52 ,  C12N9/54 ,  C12N15/62 ,  A61K39/0258 ,  B01F2101/04 ,  C07K2319/705

Abstract: The present disclosure is generally directed to an anucleated cell-based platforms for encapsulation and delivery of agricultural compounds. Disclosed herein are compositions for the stable and targeted delivery of agricultural compounds within achromosomal and/or anucleated cells. The present disclosure also provides methods of improving encapsulation and retention of agricultural compounds in achromosomal and/or anucleated cells.

公开(公告)号：US20240197852A1

公开(公告)日：2024-06-20

申请号：US18556443

申请日：2022-04-22

Applicant: Wake Forest University Health Sciences ,  UNITED STATES AS REPRESENTED BY SECRETARY OF NAVY

Inventor： Leigh Ann Sanders ,  John W. Sanders ,  Marlena Westcott ,  Kevin Porter

IPC: A61K39/095 ,  A61K39/00 ,  A61K39/02 ,  A61K39/108 ,  A61K39/112 ,  A61K41/17 ,  A61P31/04 ,  A61P37/04

CPC classification number: A61K39/095 ,  A61K39/0258 ,  A61K39/0283 ,  A61K39/105 ,  A61K41/17 ,  A61P31/04 ,  A61P37/04 ,  A61K2039/521 ,  A61K2039/575

Abstract: The present invention relates to the fields of sexually transmitted disease and immunology. More specifically, but not exclusively, the invention provides a composition and methods to prepare and administer a vaccine for Neisseria gonorrhoede and/or other gram-negative bacteria such as by using psoralen-inactivated bacteria.

公开(公告)号：US11957750B2

公开(公告)日：2024-04-16

申请号：US18213127

申请日：2023-06-22

Applicant: University of Southern California

Inventor： Brad Spellberg ,  Travis Nielsen ,  Brian Luna ,  Jun Yan

IPC: A61K36/06 ,  A61K39/00 ,  A61K39/02 ,  A61K39/085 ,  A61K39/09 ,  A61K39/104 ,  A61K39/108 ,  A61K39/39 ,  A61P37/04

CPC classification number: A61K39/39 ,  A61K36/06 ,  A61K39/0002 ,  A61K39/025 ,  A61K39/0258 ,  A61K39/0266 ,  A61K39/085 ,  A61K39/104 ,  A61P37/04 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55572

Abstract: An optimized protein-free tripartite vaccine that protects against lethal blood and lung infections caused by a variety of nosocomial pathogens across taxonomic kingdoms, including Gram-positive bacteria, Gram-negative bacteria, and fungi.